 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DIAZEPAM increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DIAZEPAM increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DIAZEPAM increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DIAZEPAM increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DIAZEPAM increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"DIAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: DIAZEPAM: precautions: Cleft palate and encephalopathy are the most common and consistently reported malformations produced in these species by administration of high, maternally toxic doses [0m
[31mof diazepam during organogenesis. Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term changes in cellular immune responses, [0m
[31mbrain neurochemistry, and behavior. Nursing Mothers Diazepam is present in breastmilk. There are reports of sedation, poor feeding, and poor weight gain in infants exposed to benzodiazepines through [0m
[31mbreast milk. Because of the potential for serious adverse reaction, including sedation and withdrawal symptoms in breastfed infants, advise patient that breastfeeding is not recommended during [0m
[31mtreatment with diazepam tablets. Pediatric Use Safety and effectiveness in pediatric patients below the age of [0m[1;31m6[0m[31m months have not been established. DIAZEPAM: precautions: Geriatric Use In elderly [0m
[31mpatients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation [0m[1;31m([0m[1;31m2[0m[31m mg to [0m[1;31m2.5[0m[31m mg once or twice daily, initially to be [0m
[31mincreased gradually as needed and tolerated[0m[1;31m)[0m[31m. Extensive accumulation of diazepam and its major metabolite, desmethyldiazepam, has been noted following chronic administration of diazepam in healthy [0m
[31melderly male subjects. Metabolites of this drug are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because [0m
[31melderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Hepatic Insufficiency Decreases in clearance [0m
[31mand protein binding, and increases in volume of distribution and half-life have been reported in patients with cirrhosis. DIAZEPAM: precautions: In such patients, a [0m[1;31m2[0m[31m- to [0m[1;31m5[0m[31m-fold increase in mean [0m
[31mhalf-life has been reported. Delayed elimination has also been reported for the active metabolite desmethyldiazepam. Benzodiazepines are commonly implicated in hepatic encephalopathy. Increases in [0m
[31mhalf-life have also been reported in hepatic fibrosis and in both acute and chronic hepatitis [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Hepatic Insufficiency [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: adverse_reactions: ADVERSE REACTIONS Side effects most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following have also been reported: Central [0m
[31mNervous System: confusion, depression, dysarthria, headache, slurred speech, tremor, vertigo Gastrointestinal System: constipation, nausea, gastrointestinal disturbances Special Senses: blurred [0m
[31mvision, diplopia, dizziness Cardiovascular System: hypotension Psychiatric and Paradoxical Reactions: stimulation, restlessness, acute hyperexcited states, anxiety, agitation, aggressiveness, [0m
[31mirritability, rage, hallucinations, psychoses, delusions, increased muscle spasticity, insomnia, sleep disturbances, and nightmares. Inappropriate behavior and other adverse behavioral effects have [0m
[31mbeen reported when using benzodiazepines. Should these occur, use of the drug should be discontinued. They are more likely to occur in children and in the elderly. DIAZEPAM: adverse_reactions: [0m
[31mUrogenital System: incontinence, changes in libido, urinary retention Skin and Appendages: skin reactions Laboratories: elevated transaminases and alkaline phosphatase Other: changes in salivation, [0m
[31mincluding dry mouth, hypersalivation Antegrade amnesia may occur using therapeutic dosages, the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior. Minor[0m
[31mchanges in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam tablets therapy and are of no known significance. Because of isolated reports of [0m
[31mneutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Postmarketing Experience Injury, Poisoning and Procedural Complications There have been[0m
[31mreports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives [0m[1;31m([0m[31mincluding alcohol[0m[1;31m)[0m[31m, and in the elderly.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: spl_medguide_table: content> Taking diazepam tablets with other medicines used to treat epilepsy can cause an increase in the number or severity of grand mal seizures. [0m
[1;31m<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Diazepam tablets can make you sleepy or dizzy, and can slow your thinking and motor skills.<[0m[31m/[0m[31mcontent[0m[31m><list [0m
[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>o<[0m[31m/[0m[31mcaption[0m[31m>Do not drive, operate heavy machinery, or do other dangerous activities until you know how diazepam tablets affect [0m
[31myou.<[0m[31m/[0m[31mitem[0m[31m><item><caption>o<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking diazepam tablets without first talking to your [0m
[31mhealthcare provider. <[0m[31m/[0m[31mcontent[0m[31m>When taken with alcohol or drugs that cause sleepiness or dizziness, diazepam tablets may make your sleepiness or dizziness much worse. DIAZEPAM: spl_medguide_table: [0m
[31mitem><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Like other antiepileptic drugs, diazepam tablets may cause suicidal thoughts or actions in a very small number of people, [0m
[31mabout [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. DIAZEPAM: spl_medguide_table: content> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry[0m
[31myou:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>thoughts about suicide or [0m
[31mdying<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>new or worse depression<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>feeling agitated or restless<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>trouble sleeping [0m
[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>acting aggressive, being angry, or violent<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>other unusual changes in behavior or [0m
[31m<paragraph>mood<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m DIAZEPAM: spl_medguide_table: "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>attempts to commit [0m
[31msuicide<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>new or worse anxiety or irritability<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>an extreme increase in activity and talking [0m
[1;31m([0m[31mmania[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>new or worse panic attacks<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>acting on dangerous impulses<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How can I watch for early symptoms of suicidal thoughts and actions?<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m
[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. DIAZEPAM: spl_medguide_table: [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><item><caption>&#x2022;<[0m[31m/[0m[31mcaption[0m[31m>Keep all follow-up visits with your healthcare provider as scheduled. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph>Call your healthcare provider between visits as needed, [0m
[31mespecially if you are worried about symptoms.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph[0m[1;31m>[0m[31mSuicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare[0m
[31mprovider may check for other causes.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: information_for_patients: Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or [0m
[31msymptoms; and on the proper disposal of unused drug [0m[1;31m([0m[31msee WARNINGS: Abuse, Misuse, and Addiction and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. Withdrawal Reactions Inform patients that the continued use of diazepam[0m
[31mtablets may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of diazepam tablets may precipitate acute withdrawal reactions, which can be [0m
[31mlife-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m months. [0m
[31mInstruct patients that discontinuation or dosage reduction of diazepam tablets may require a slow taper [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. DIAZEPAM: [0m
[31minformation_for_patients: Patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during diazepam tablets therapy. As is true of most CNS-acting drugs, [0m
[31mpatients receiving diazepam tablets should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle. Pregnancy[0m
[31mAdvise pregnant females that use of diazepam tablets late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, lethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, [0m
[31mrestlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in newborns [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. Instruct patients to inform [0m
[31mtheir healthcare provider if they are pregnant. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to diazepam tablets during pregnancy [0m[1;31m([0m[31msee [0m
[31mPrecautions , Pregnancy [0m[1;31m)[0m[31m. DIAZEPAM: information_for_patients: Nursing Advise patients that breastfeeding is not recommended during treatment with diazepam tablets [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m.[0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: dependence: Dependence Physical Dependence Diazepam tablets may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of [0m
[31mphysiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or[0m
[31mrapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. [0m
[31mPatients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages [0m[1;31m([0m[31mi.e., higher and/or more frequent [0m
[31mdoses[0m[1;31m)[0m[31m, those who have had longer durations of use [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions [0m[1;31m)[0m[31m. DIAZEPAM: dependence: To reduce the risk of withdrawal reactions, use a gradual taper to [0m
[31mdiscontinue diazepam tablets or reduce the dosage [0m[1;31m([0m[31msee DOSAGE and ADMINISTRATION: Discontinuation or Dosage Reduction of Diazepam Tablets and WARNINGS: Dependence and Withdrawal Reactions [0m[1;31m)[0m[31m. Acute [0m
[31mWithdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, [0m
[31mderealization, dizziness, fatigue, gastrointestinal adverse reactions [0m[1;31m([0m[31me.g., nausea, vomiting, diarrhea, weight loss, decreased appetite[0m[1;31m)[0m[31m, headache, hyperacusis, hypertension, irritability, insomnia, [0m
[31mmemory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. DIAZEPAM: dependence: More severe acute withdrawal signs and symptoms, including [0m
[31mlife-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. Protracted Withdrawal Syndrome Protracted [0m
[31mwithdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms [0m[1;31m([0m[31me.g., weakness, tremor, muscle twitches[0m[1;31m)[0m[31m, [0m
[31mparesthesia, and tinnitus that persists beyond [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than [0m[1;31m12[0m[31m months. As a result, there may be [0m
[31mdifficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used; however, little tolerance develops to the [0m
[31mamnestic reactions and other cognitive impairments caused by benzodiazepines.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS â€¢ Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. â€¢ The use of benzodiazepines, [0m
[31mincluding diazepam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. DIAZEPAM: boxed_warning: Before prescribing diazepam tablets and [0m
[31mthroughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . â€¢ The continued use of benzodiazepines, including diazepam tablets, may lead to clinically [0m
[31msignificant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of diazepam [0m
[31mtablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam tablets [0m
[31mor reduce the dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m .         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: risks: Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [0m[1;31m([0m[31msee WARNINGS: [0m
[31mNeonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear [0m
[31massociation with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data [0m[1;31m)[0m[31m. Diazepam has been shown to be teratogenic in mice and hamsters when given orally at daily doses of [0m[1;31m100[0m[31m mg/kg or greater [0m
[1;31m([0m[31mapproximately eight times the maximum recommended human dose [0m[1;31m[[0m[31mMRHD[0m[31m=[0m[1;31m1[0m[31m mg/kg/day[0m[1;31m][0m[31m or greater on a mg/m [0m[1;31m2[0m[31m basis[0m[1;31m)[0m[31m. Cleft palate and encephalopathy are the most common and consistently reported [0m
[31mmalformations produced in these species by administration of high, maternally toxic doses of diazepam during organogenesis. The background risk of major birth defects and miscarriage for the indicated[0m
[31mpopulation is unknown. DIAZEPAM: risks: All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth [0m
[31mdefects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m


[31mCONTENT: DIAZEPAM: clinical_pharmacology: Diazepam accumulates upon multiple dosing and there is some evidence that the terminal elimination half-life is slightly prolonged. Pharmacokinetics in [0m
[31mSpecial Populations Children In children [0m[1;31m3[0m[31m-[0m[1;31m8[0m[31m years old the mean half-life of diazepam has been reported to be [0m[1;31m18[0m[31m hours. Newborns In full term infants, elimination half-lives around [0m[1;31m30[0m[31m hours have been [0m
[31mreported, with a longer average half-life of [0m[1;31m54[0m[31m hours reported in premature infants of [0m[1;31m28[0m[31m-[0m[1;31m34[0m[31m weeks gestational age and [0m[1;31m8[0m[31m-[0m[1;31m81[0m[31m days post-partum. In both premature and full term infants the active [0m
[31mmetabolite desmethyldiazepam shows evidence of continued accumulation compared to children. Longer half-lives in infants may be due to incomplete maturation of metabolic pathways. Geriatric [0m
[31mElimination half-life increases by approximately [0m[1;31m1[0m[31m hour for each year of age beginning with a half-life of [0m[1;31m20[0m[31m hours at [0m[1;31m20[0m[31m years of age. DIAZEPAM: clinical_pharmacology: This appears to be due to an [0m
[31mincrease in volume of distribution with age and a decrease in clearance. Consequently, the elderly may have lower peak concentrations, and on multiple dosing higher trough concentrations. It will also[0m
[31mtake longer to reach steady-state. Conflicting information has been published on changes of plasma protein binding in the elderly. Reported changes in free drug may be due to significant decreases in [0m
[31mplasma proteins due to causes other than simply aging. Hepatic Insufficiency In mild and moderate cirrhosis, average half-life is increased. The average increase has been variously reported from [0m
[1;31m2[0m[31m-fold to [0m[1;31m5[0m[31m-fold, with individual half-lives over [0m[1;31m500[0m[31m hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. DIAZEPAM: [0m
[31mclinical_pharmacology: Mean half-life is also prolonged with hepatic fibrosis to [0m[1;31m90[0m[31m hours [0m[1;31m([0m[31mrange [0m[1;31m66[0m[31m-[0m[1;31m104[0m[31m hours[0m[1;31m)[0m[31m, with chronic active hepatitis to [0m[1;31m60[0m[31m hours [0m[1;31m([0m[31mrange [0m[1;31m26[0m[31m-[0m[1;31m76[0m[31m hours[0m[1;31m)[0m[31m, and with acute viral [0m
[31mhepatitis to [0m[1;31m74[0m[31m hours [0m[1;31m([0m[31mrange [0m[1;31m49[0m[31m-[0m[1;31m129[0m[1;31m)[0m[31m. In chronic active hepatitis, clearance is decreased by almost half.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mIAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Diazepam has been reported to cause increases in half-life and delayed elimination in patients with hepatic insufficiency, including those with hepatic fibrosis and both acute and chronic [0m
[32mhepatitis. While the label does not explicitly state that diazepam increases the risk of acute liver injury, it does indicate that caution should be exercised in patients with impaired liver function,[0m
[32mas the drug's metabolism and clearance are affected in such conditions.[0m

[32mSOURCE: DIAZEPAM label[0m
[32mEXTRACT_START_END: Hepatic Insufficiency Decreases in clearance [0m[32m...[0m[32m chronic hepatitis [0m[1;32m([0m[32msee CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Hepatic Insufficiency [0m[1;32m)[0m[32m.[0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Diazepam has been reported to cause increases in half-life and[0m
[34mdelayed elimination in patients with hepatic insufficiency, including those with hepatic fibrosis and both acute and chronic hepatitis. While the label does not explicitly state that diazepam [0m
[34mincreases the risk of acute liver injury, it does indicate that caution should be exercised in patients with impaired liver function, as the drug's metabolism and clearance are affected in such [0m
[34mconditions.[0m

[34mSOURCE: DIAZEPAM label[0m
[34mEXTRACT_START_END: Hepatic Insufficiency Decreases in clearance [0m[34m...[0m[34m chronic hepatitis [0m[1;34m([0m[34msee CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Hepatic Insufficiency [0m[1;34m)[0m[34m.[0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DIAZEPAM increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if DIAZEPAM increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that while the label does not explicitly state that diazepam increases the risk of acute liver injury, it does indicate that caution should be exercised in patients with [0m
[32mimpaired liver function. Diazepam has been reported to cause increases in half-life and delayed elimination in patients with hepatic insufficiency, including those with hepatic fibrosis and both acute[0m
[32mand chronic hepatitis. This suggests that diazepam's metabolism and clearance are affected in conditions of impaired liver function."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label data does not explicitly state that diazepam increases the risk of acute liver injury. However, it does indicate that diazepam's pharmacokinetics are altered in patients [0m
[32mwith hepatic insufficiency, which includes conditions such as hepatic fibrosis and hepatitis. This suggests that there is a potential for increased risk or exacerbation of liver injury in patients [0m
[32mwith pre-existing liver conditions, and therefore caution is advised when prescribing diazepam to such patients. The degree of risk for acute liver injury specifically due to diazepam in patients [0m
[32mwithout pre-existing liver conditions is not clearly stated in the FDA label data."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DIAZEPAM increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if DIAZEPAM increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that while the label does not explicitly state that diazepam increases the risk of acute liver injury, it does indicate that caution should be exercised in patients with [0m
[34mimpaired liver function. Diazepam has been reported to cause increases in half-life and delayed elimination in patients with hepatic insufficiency, including those with hepatic fibrosis and both acute[0m
[34mand chronic hepatitis. This suggests that diazepam's metabolism and clearance are affected in conditions of impaired liver function."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label data does not explicitly state that diazepam increases the risk of acute liver injury. However, it does indicate that diazepam's pharmacokinetics are altered in patients [0m
[34mwith hepatic insufficiency, which includes conditions such as hepatic fibrosis and hepatitis. This suggests that there is a potential for increased risk or exacerbation of liver injury in patients [0m
[34mwith pre-existing liver conditions, and therefore caution is advised when prescribing diazepam to such patients. The degree of risk for acute liver injury specifically due to diazepam in patients [0m
[34mwithout pre-existing liver conditions is not clearly stated in the FDA label data."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DIAZEPAM increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if DIAZEPAM increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that while the label does not explicitly state that diazepam increases the risk of acute liver injury, it does indicate that caution should be exercised in patients with [0m
[31mimpaired liver function. Diazepam has been reported to cause increases in half-life and delayed elimination in patients with hepatic insufficiency, including those with hepatic fibrosis and both acute[0m
[31mand chronic hepatitis. This suggests that diazepam's metabolism and clearance are affected in conditions of impaired liver function.[0m
[31m        -----[0m
[31m        Final answer: The FDA label data does not explicitly state that diazepam increases the risk of acute liver injury. However, it does indicate that diazepam's pharmacokinetics are altered in [0m
[31mpatients with hepatic insufficiency, which includes conditions such as hepatic fibrosis and hepatitis. This suggests that there is a potential for increased risk or exacerbation of liver injury in [0m
[31mpatients with pre-existing liver conditions, and therefore caution is advised when prescribing diazepam to such patients. The degree of risk for acute liver injury specifically due to diazepam in [0m
[31mpatients without pre-existing liver conditions is not clearly stated in the FDA label data.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-DIAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether DIAZEPAM increases or decreases the risk of acute liver injury. Based on the information provided by FDAHandler, the FDA label does not explicitly state that diazepam [0m
[32mincreases the risk of acute liver injury. However, it does indicate that diazepam's pharmacokinetics are altered in patients with hepatic insufficiency, which includes conditions such as hepatic [0m
[32mfibrosis and hepatitis. This suggests that there is a potential for increased risk or exacerbation of liver injury in patients with pre-existing liver conditions, and therefore caution is advised when[0m
[32mprescribing diazepam to such patients. The degree of risk for acute liver injury specifically due to diazepam in patients without pre-existing liver conditions is not clearly stated in the FDA label [0m
[32mdata.[0m
